Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 7:19:1582902.
doi: 10.3389/fncel.2025.1582902. eCollection 2025.

The potential of repurposing clemastine to promote remyelination

Reiji Yamazaki  1 , Nobuhiko Ohno  1   2
Affiliations
Review

The potential of repurposing clemastine to promote remyelination

Reiji Yamazaki et al. Front Cell Neurosci. .

Abstract

White matter in the central nervous system comprises bundled nerve fibers myelinated by oligodendrocytes. White matter injury, characterized by the loss of oligodendrocytes and myelin, is common after ischemic brain injury, inflammatory demyelinating diseases including multiple sclerosis, and traumatic damage such as spinal cord injury. Currently, no therapies have been confirmed to promote remyelination in these diseases. Over the past decade, various reports have suggested that the anti-muscarinic drug clemastine can stimulate remyelination by oligodendrocytes. Consequently, the repurposing of clemastine as a potential treatment for a variety of neurological disorders has gained significant attention. The therapeutic effects of clemastine have been demonstrated in various animal models, and its mechanisms of action in various neurological disorders are currently being investigated. In this review, we summarize reports relating to clemastine administration for white matter injury and neurological disease and discuss the therapeutic potential of remyelination promotion.

Keywords: clemastine; drug repositioning; oligodendrocyte; remyelination; white matter injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Therapeutic effects of clemastine in a mouse model of white matter injury and molecular mechanisms of action in oligodendrocyte precursor cells. (A) The animal models of white matter injury are induced demyelination, oligodendrocyte loss, motor paralysis and sensory paralysis. Motor function and remyelination state of oligodendrocytes (OLs) are assessed by behavioral tests and histological analysis. Clemastine administration in these animal models promotes remyelination and functional recovery. (B) Clemastine administration activates the extracellular signal-regulated kinase (ERK) pathway to promote differentiation via inhibition of the M1 muscarinic acetylcholine receptor (CHRM1) in oligodendrocyte precursor cells (OPCs). Clemastine also induces the activation of H3K9 histone methyltransferases and the glutathione S-transferase 4α (Gsta4)/4-hydroxynonenal (4-HNE) pathway in OPCs. In addition, clemastine promotes the N-methyl-d-aspartate (NMDA) receptor-rich state in OPCs. Shown are the schematic diagram of oligodendrocyte (OL) differentiation and stage-specific markers.
See this image and copyright information in PMC

References

    1. Bercury K. K., Macklin W. B. (2015). Dynamics and mechanisms of CNS myelination. Dev. Cell 32, 447–458. doi: 10.1016/j.devcel.2015.01.016, PMID: - DOI - PMC - PubMed
    1. Blakemore W. F., Franklin R. J. (2008). Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 318, 193–212. doi: 10.1007/978-3-540-73677-6_8, PMID: - DOI - PubMed
    1. Carlström K. E., Zhu K., Ewing E., Krabbendam I. E., Harris R. A., Falcão A. M., et al. (2020). Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-bid-axis. Nat. Commun. 11:4071. doi: 10.1038/s41467-020-17871-5, PMID: - DOI - PMC - PubMed
    1. Caverzasi E., Papinutto N., Cordano C., Kirkish G., Gundel T. J., Zhu A., et al. (2023). MWF of the corpus callosum is a robust measure of remyelination: results from the ReBUILD trial. Proc. Natl. Acad. Sci. USA 120:e2217635120. doi: 10.1073/pnas.2217635120, PMID: - DOI - PMC - PubMed
    1. Chamberlain K. A., Chapey K. S., Nanescu S. E., Huang J. K. (2017). Creatine enhances mitochondrial-mediated oligodendrocyte survival after demyelinating injury. J. Neurosci. 37, 1479–1492. doi: 10.1523/JNEUROSCI.1941-16.2016, PMID: - DOI - PMC - PubMed

LinkOut - more resources